EN
Human Apolipoprotein CIII
Delipidated whole molecule
Product Overview, Sizes and Prices | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proteins Synonyms: ApoCIII, ApoC3 Source: Human Plasma Purity: ≥ 95% by SDS-PAGE Physical State: Frozen in 10 mM NH4HCO3, pH 7.4 Manufacturer: |
|
|||||||||||||||||
Athens Research & Technology
Produktdetails
Synonyms
ApoCIII, ApoC3
Description of Human Apolipoprotein CIII
Human Apolipoprotein CIII is a 8.75 kDa protein. Apolipoprotein CIII (ApoCIII) is a 79-amino acid glycoprotein primarily synthesized in the liver and intestine, circulating on triglyceride-rich lipoproteins (TRLs) such as VLDL, chylomicrons, and HDL. Functionally, ApoCIII inhibits lipoprotein lipase (LPL) activity by displacing its activator ApoCII, thereby reducing triglyceride hydrolysis and delaying hepatic clearance of TRLs via LDL receptor-related protein 1 (LRP1) and syndecan-1 pathways. It also promotes VLDL secretion under lipid-rich conditions, exacerbating hypertriglyceridemia. Clinically, elevated ApoCIII levels (>15 mg/dL) correlate with hypertriglyceridemia, atherosclerosis, and coronary heart disease, while loss-of-function variants reduce cardiovascular risk by 40%. ApoCIII overexpression induces insulin resistance by impairing skeletal muscle glucose uptake and pancreatic β-cell function, with elevated plasma levels predicting type 2 diabetes progression. Therapeutically, ApoCIII is targeted using antisense oligonucleotides (e.g., volanesorsen), which lower triglycerides by 70–80% in familial chylomicronemia syndrome, and RARα agonists like AM580 that suppress hepatic ApoCIII synthesis via HNF4α downregulation. Synthetic ApoCII mimetics (C-II-a) counteract ApoCIII-mediated LPL inhibition3, while dual APOC3/APOB gene silencing strategies show promise for combined dyslipidemias. Normal plasma concentrations (8–15 mg/dL) serve as biomarkers for cardiovascular risk stratification, particularly in diabetic populations. Emerging evidence positions ApoCIII inhibition as a dual therapeutic approach for metabolic and cardiovascular diseases.
Source
Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
Storage
For long term, store Human Apolipoprotein CIII at ≤ -80°C.
Applications
In Vitro Diagnostics, Cardiovascular Research, Diabetes.
Citations/Publications
Deng, M. et al., (2018), 'LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration', Nature, 562: pp 605–609. Available at: https://doi.org/10.1038/s41586-018-0615-z
Kegulian, N. C., et al., (2019), 'ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors', Arterioscler Thromb Vasc Biol., 39: pp 2145–2156. Available at: DOI: 10.1161/ATVBAHA.119.312723
NCBI: https://www.ncbi.nlm.nih.gov/protein/P02656
Shipped with dry ice
Gel Scan of Human Apolipoprotein CIII
| Fig. 1: SDS-PAGE Gel |
Usage: For research use only. Not for use in diagnostic or therapeutic procedures. Not for human use.
To buy Human Apolipoprotein CIII please click on the Shopping List Symbol right from the indicated price. This will add Human Apolipoprotein CIII to your Shopping List. You can then click on the button »Shopping List & Order Form« to ask for a quote. We will send you your quote as soon as possible. Our offer will include institutional discounts where applicable.
For business customers only. All prices are net prices (excluding VAT). Final prices in our quote will contain VAT plus shipping costs if applicable. For further information please go to our Shipping page.
Errors, changes and availability excepted.
Payment Methods
Paying by bank transfer
